PURPOSE: To identify NANDA-I diagnoses that are most relevant to hematology-oncology nursing in Europe. METHODS: In a two-round, electronic, quantitative Delphi study, 28 experts from nine European countries assessed the relevance of NANDA-I diagnoses and health problems. FINDINGS: This study identified 64 relevant diagnoses and three health problems. All experts listed 11 diagnoses: "imbalanced nutrition: less than body requirements,""diarrhea,""fatigue,""risk for bleeding,""risk for infection,""impaired oral mucous membrane,""risk for impaired skin integrity,""impaired skin integrity,""hyperthermia,""nausea,""acute pain," and the health problem "pruritis." CONCLUSIONS AND IMPLICATIONS FOR PRACTICE: The "NANDA-I classification 2009-2011" describes, in almost all disease- and treatment-related problems, nursing diagnoses as relevant to the adult patient with hematological malignancy. These diagnoses are therefore recommended.
PURPOSE: To identify NANDA-I diagnoses that are most relevant to hematology-oncology nursing in Europe. METHODS: In a two-round, electronic, quantitative Delphi study, 28 experts from nine European countries assessed the relevance of NANDA-I diagnoses and health problems. FINDINGS: This study identified 64 relevant diagnoses and three health problems. All experts listed 11 diagnoses: "imbalanced nutrition: less than body requirements,""diarrhea,""fatigue,""risk for bleeding,""risk for infection,""impaired oral mucous membrane,""risk for impaired skin integrity,""impaired skin integrity,""hyperthermia,""nausea,""acute pain," and the health problem "pruritis." CONCLUSIONS AND IMPLICATIONS FOR PRACTICE: The "NANDA-I classification 2009-2011" describes, in almost all disease- and treatment-related problems, nursing diagnoses as relevant to the adult patient with hematological malignancy. These diagnoses are therefore recommended.
Authors: Carlo Barone; Carmine Pinto; Nicola Normanno; Lorenzo Capussotti; Francesco Cognetti; Alfredo Falcone; Lorenzo Mantovani Journal: PLoS One Date: 2014-01-20 Impact factor: 3.240